Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited announced a change in the interests of its director, Dr. Eric Rose, who increased his holdings in the company through the acquisition of 30,310 American Depositary Shares (ADS) on the Nasdaq, valued at approximately US$506,214.54. This on-market purchase reflects confidence in the company’s prospects and may have implications for the perception of Mesoblast’s market position and stakeholder interest.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company focused on developing regenerative medicine products. The company specializes in the development of innovative cellular therapies based on its proprietary mesenchymal lineage adult stem cell technology. Mesoblast’s primary market focus includes treating severe and life-threatening diseases in areas such as inflammatory ailments, cardiovascular disorders, and cancer.
YTD Price Performance: 5.45%
Average Trading Volume: 123,813
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.95B
See more insights into MSB stock on TipRanks’ Stock Analysis page.
